Evaluation of the diagnostic accuracy of two point-of-care tests for COVID-19 when used in symptomatic patients in community settings in the UK primary care COVID diagnostic accuracy platform trial (RAPTOR-C19)
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0288612 ↗Kurz gefasst
Klinische Studie in der Zeitschrift PLOS ONE, 2023. Verfasst von Brian D Nicholson und 13 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health, Wellcome Trust, NIHR Applied Research Collaboration Oxford and Thames Valley at Oxford Health NHS Foundation Trust.
Abstract (Originalsprache)
Background and objective Point-of-care lateral flow device antigen testing has been used extensively to identify individuals with active SARS-CoV-2 infection in the community. This study aimed to evaluate the diagnostic accuracy of two point-of-care tests (POCTs) for SARS-CoV-2 in routine community care.
Methods
Adults and children with symptoms consistent with suspected current COVID-19 infection were prospectively recruited from 19 UK general practices and two COVID-19 testing centres between October 2020 and October 2021. Participants were tested by trained healthcare workers using at least one of two index POCTs (Roche-branded SD Biosensor Standard™ Q SARS-CoV-2 Rapid Antigen Test and/or BD Veritor™ System for Rapid Detection of SARS-CoV-2). The reference standard was laboratory triplex reverse transcription quantitative PCR (RT-PCR) using a combined nasal/oropharyngeal swab. Diagnostic accuracy parameters were estimated, with 95% confidence intervals (CIs), overall, in relation to RT-PCR cycle threshold and in pre-specified subgroups.
Results
Of 663 participants included in the primary analysis, 39.2% (260/663, 95% CI 35.5% to 43.0%) had a positive RT-PCR result. The SD Biosensor POCT had sensitivity 84.0% (178/212, 78.3% to 88.6%) and specificity 98.5% (328/333, 96.5% to 99.5%), and the BD Veritor POCT had sensitivity 76.5% (127/166, 69.3% to 82.7%) and specificity 98.8% (249/252, 96.6% to 99.8%) compared with RT-PCR. Sensitivity of both devices dropped substantially at cycle thresholds ≥30 and in participants more than 7 days after onset of symptoms.
Conclusions
Both POCTs assessed exceed the Medicines and Healthcare products Regulatory Agency target product profile’s minimum acceptable specificity of 95%. Confidence intervals for both tests include the minimum acceptable sensitivity of 80%. In symptomatic patients, negative results on these two POCTs do not preclude the possibility of infection. Tests should not be expected to reliably detect disease more than a week after symptom onset, when viral load may be reduced. Registration ISRCTN142269 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
- Immunisation and Vaccine Preventable Diseases Division and Public Health Programmes, UK Health Security Agency, London, United Kingdom.
- Influenza and Respiratory Virology & Polio Reference Service, UK Health Security Agency, London, United Kingdom.
- NIHR Health Protection Research Unit, Imperial College London, London, United Kingdom.
- Division of Cardiovascular Science, University of Manchester, Manchester, United Kingdom.
- Emergency Department, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
ORCID-Profile: Brian D Nicholson, Philip J Turner, Alice J Williams, Richard Body, Simon de Lusignan
Förderung
- Department of Health
- Wellcome Trust
- NIHR Applied Research Collaboration Oxford and Thames Valley at Oxford Health NHS Foundation Trust
- University of Oxford Medical Sciences Division Benefactors Urgent COVID-19 Fund
- The National Institute for Health and Care Research (NIHR) School for Primary Care Research
- NIHR and Asthma + Lung UK
- NIHR Community Healthcare MedTech and In Vitro Diagnostics Co-operative at Oxford Health NHS Foundation Trust
- Oxford Martin School
Zitieren
APA
Nicholson, B. D., Turner, P. J., Fanshawe, T. R., Williams, A. J., Amirthalingam, G., Tonner, S., Zambon, M., Body, R., Davies, K., Perera, R., de Lusignan, S., Hayward, G. N., Hobbs, F. D. R., & RAPTOR-C19 Study Group and the CONDOR Steering Committee (2023). Evaluation of the diagnostic accuracy of two point-of-care tests for COVID-19 when used in symptomatic patients in community settings in the UK primary care COVID diagnostic accuracy platform trial (RAPTOR-C19). PLOS ONE. https://doi.org/10.1371/journal.pone.0288612
Vancouver
Nicholson BD, Turner PJ, Fanshawe TR, Williams AJ, Amirthalingam G, Tonner S, et al. Evaluation of the diagnostic accuracy of two point-of-care tests for COVID-19 when used in symptomatic patients in community settings in the UK primary care COVID diagnostic accuracy platform trial (RAPTOR-C19). PLOS ONE. 2023. doi:10.1371/journal.pone.0288612
BibTeX
@article{Nicholson2023,
author = {Nicholson, Brian D and Turner, Philip J and Fanshawe, Thomas R and Williams, Alice J and Amirthalingam, Gayatri and Tonner, Sharon and Zambon, Maria and Body, Richard and Davies, Kerrie and Perera, Rafael and de Lusignan, Simon and Hayward, Gail N and Hobbs, F D Richard and RAPTOR-C19 Study Group and the CONDOR Steering Committee, RAPTOR-C19 Study Group and the CONDOR Steering Committee},
title = {Evaluation of the diagnostic accuracy of two point-of-care tests for COVID-19 when used in symptomatic patients in community settings in the UK primary care COVID diagnostic accuracy platform trial (RAPTOR-C19)},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0288612}
}
EUVIMED